These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33812689)

  • 1. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
    Zivelonghi C; Zekeridou A
    J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
    Valencia-Sanchez C; Zekeridou A
    Front Neurol; 2021; 12():642800. PubMed ID: 33897597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
    J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
    Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
    Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    Sechi E; Zekeridou A
    J Thorac Oncol; 2021 Mar; 16(3):381-394. PubMed ID: 33188910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
    McCombe JA; Sechi E; Zekeridou A
    Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
    Pan PC; Haggiagi A
    Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.
    Duong SL; Prüss H
    Neurotherapeutics; 2022 Apr; 19(3):848-863. PubMed ID: 35043373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
    Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
    Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
    Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
    Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
    Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
    J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
    Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
    J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
    Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.
    Urban H; Steidl E; Hattingen E; Filipski K; Meissner M; Sebastian M; Koch A; Strzelczyk A; Forster MT; Baumgarten P; Ronellenfitsch MW; Steinbach JP; Voss M
    Front Immunol; 2021; 12():798811. PubMed ID: 35046955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
    Zammit F; Seront E
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
    Seki M; Kitano S; Suzuki S
    Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
    Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
    Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.